At mid-range doses (1.0 mg), real-world data suggests weight loss approaching what the maximum dose achieves
For patients with joint pain, fatigue, or deconditioning, the plan should be individualized rather than generic
Serious potential risks include allergic reactions, pancreatitis, gallbladder problems, changes in blood sugar, kidney problems, increased heart rate, and mental health changes
Both semaglutide and tirzepatide have not been studied extensively in pregnant women, but animal studies suggest potential risks to fetal development, including: Fetal growth restriction Structural abnormalities Miscarriage (observed in animal studies at high doses) Stillbirth, animal studies show risk at all doses